Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of
topical tapinarof cream, 1% in subjects with atopic dermatitis. Subjects in this study have
completed treatment in one of two Phase 3 pivotal studies (DMVT-505-3101 or DMVT-505-3102) or
completed treatment in the DMVT-505-2104 study, or directly enrolled into this study. This
study will consist of up to 48 weeks of treatment and a 1 week safety follow-up period.